{
    "clinical_study": {
        "@rank": "82336", 
        "arm_group": [
            {
                "arm_group_label": "Dose 1 Active", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Dose 2 Active", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Dose 3 Active", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Dose 4 Active", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Dose 5 Active", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Dose 6 Active", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Dose 7 Active", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Dose 1 Placebo", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "Dose 2 Placebo", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "Dose 3 Placebo", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "Dose 4 Placebo", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "Dose 5 Placebo", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "Dose 6 Placebo", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "Dose 7 Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will test single doses of the study drug in increasing amounts to see if it is\n      safe."
        }, 
        "brief_title": "Study Comparing the Pharmacokinetics, Pharmacodynamics, and Safety of K-312 in Healthy Adult Volunteers", 
        "condition": "Safety and Tolerability", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject provides written informed consent before any study-specific evaluation is\n             performed.\n\n          -  Subject is a healthy adult male or a female of non-childbearing potential between the\n             ages of 18 and 45 years, inclusive.\n\n          -  Subject has a body mass index of 18.5 to 32 kg/m2, inclusive.\n\n        Exclusion Criteria:\n\n          -  Subject is a woman who is of childbearing potential or is breastfeeding.\n\n          -  Subject has the presence of an active or recurring clinically significant\n             cardiovascular, pulmonary, renal, endocrine, hepatic, neurologic, psychiatric,\n             immunologic, hematologic, gastrointestinal, or metabolic disease requiring medical\n             treatment."
            }, 
            "gender": "Both", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "September 19, 2013", 
        "id_info": {
            "nct_id": "NCT01952548", 
            "org_study_id": "K-312-1.01US"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Dose 1 Active", 
                    "Dose 2 Active", 
                    "Dose 3 Active", 
                    "Dose 4 Active", 
                    "Dose 5 Active", 
                    "Dose 6 Active", 
                    "Dose 7 Active"
                ], 
                "intervention_name": "K-312", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Dose 1 Placebo", 
                    "Dose 2 Placebo", 
                    "Dose 3 Placebo", 
                    "Dose 4 Placebo", 
                    "Dose 5 Placebo", 
                    "Dose 6 Placebo", 
                    "Dose 7 Placebo"
                ], 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "lastchanged_date": "December 30, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Austin", 
                    "country": "United States", 
                    "state": "Texas"
                }
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Adverse Events", 
            "time_frame": "10 Days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01952548"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Kowa Research Institute, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Kowa Research Institute, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}